{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1382262944274607751.json","@type":"Researcher","foaf:Person":[{"foaf:name":[{"@value":"Michael J. Moon"}],"foaf:familyName":[{"@value":"Moon"}],"foaf:givenName":[{"@value":"Michael J."}]}],"career":[{"institution":{"notation":[{"@value":"Department of Chemistry, ‡Department of Biology, §Department of Drug\rSafety and Disposition, Seragon Pharmaceuticals, 12780 El Camino Real, Suite 302, San Diego, California 92130, United States"}]}}],"product":[{"@id":"https://cir.nii.ac.jp/crid/1362262944274607872","@type":"Article","productIdentifier":[{"@type":"DOI","@value":"10.1021/acs.jmedchem.5b00054"},{"@type":"URI","@value":"https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.5b00054"}],"notation":[{"@value":"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts"}],"relation":[{"type":"creator"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1021/acs.jmedchem.5b00054_WBshKV55JkO0yTmhfTaun0sBVPe"}]}